Giredestrant significantly improved IDFS over SOC endocrine therapy, reducing the risk of invasive disease recurrence or ...

Researchers sought to determine whether zanubrutinib plus obinutuzumab would be effective in treating patients with R/R FL.

Critical illness poses a significant global health challenge, disproportionately affecting low- and middle-income countries ...

Parents at Haugan Elementary in Albany Park say the school is overcrowded and are upset Chicago Public Schools denied their ...

Studies presented at the ASH Annual Meeting 2025 highlighted a novel prognostic approach and emerging treatment strategies in lymphoma.

Younger age at diagnosis did not appear to affect outcomes among women with breast cancer who harbor BRCA mutations, ...

This math says that a typical Californian card balance is equivalent to eight days’ worth of the average wage. That ties Connecticut for the fourth-lowest burden among the states.

Giredestrant significantly improved IDFS in ER-positive, HER2-negative early breast cancer, reducing recurrence or death risk by 30% compared to SOC endocrine therapy. Subgroup analyses showed ...

The ICM+ AI model demonstrated superior prognostic value for breast cancer recurrence compared to Oncotype DX, especially for late distant recurrences. Integration of pathomic imaging in the ICM+ ...

Whether a nuclear renaissance actually occurs in the coming decade or two depends on three fundamental questions: Are the new ...

New structure opens up 10 kilometres of potential strike length along the Mishibishu Deformation Zone; 2026 drilling will ...

Expanded indication for AKEEGA® (niraparib and abiraterone acetate dual-action tablet) plus prednisone marks the first FDA-approved precision medicine ...